Cantargia Future Growth

Future criteria checks 0/6

Cantargia's earnings are forecast to decline at 52.7% per annum while its annual revenue is expected to grow at 149.7% per year. EPS is expected to grow by 10.1% per annum.

Key information

-52.7%

Earnings growth rate

10.1%

EPS growth rate

Biotechs earnings growth	36.5%
Revenue growth rate	149.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	13 Nov 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BATS-CHIXE:CANTAS - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	441	-893	-246	-873	2
12/31/2024	N/A	-249	-222	-247	3
12/31/2023	N/A	-298	-306	-296	3
9/30/2023	N/A	-299	-299	-292	N/A
6/30/2023	N/A	-293	-295	-287	N/A
3/31/2023	N/A	-330	-320	-313	N/A
12/31/2022	N/A	-372	-366	-359	N/A
9/30/2022	N/A	-385	-387	-387	N/A
6/30/2022	N/A	-419	-419	-419	N/A
3/31/2022	N/A	-411	-406	-406	N/A
12/31/2021	N/A	-367	-347	-346	N/A
9/30/2021	N/A	-319	-302	-301	N/A
6/30/2021	N/A	-255	-231	-230	N/A
3/31/2021	N/A	-206	-187	-186	N/A
12/31/2020	N/A	-173	-165	-156	N/A
9/30/2020	N/A	-153	-165	-149	N/A
6/30/2020	N/A	-139	-151	-135	N/A
3/31/2020	N/A	-127	-144	-129	N/A
12/31/2019	N/A	-111	-118	-111	N/A
9/30/2019	N/A	-102	-97	-97	N/A
6/30/2019	N/A	-98	-92	-92	N/A
3/31/2019	N/A	-101	-88	-88	N/A
12/31/2018	N/A	-91	-105	-105	N/A
9/30/2018	N/A	-78	-72	-72	N/A
6/30/2018	N/A	-68	-65	-65	N/A
3/31/2018	N/A	-56	-54	-54	N/A
12/31/2017	N/A	-60	-41	-41	N/A
9/30/2017	N/A	-65	-69	-69	N/A
6/30/2017	N/A	-66	N/A	-64	N/A
3/31/2017	N/A	-58	N/A	-54	N/A
12/31/2016	N/A	-47	N/A	-42	N/A
9/30/2016	N/A	-34	N/A	-26	N/A
6/30/2016	N/A	-24	N/A	-21	N/A
3/31/2016	N/A	-22	N/A	-19	N/A
12/31/2015	N/A	-17	N/A	-30	N/A
9/30/2015	N/A	-15	N/A	-35	N/A
6/30/2015	N/A	-14	N/A	-13	N/A
3/31/2015	N/A	-10	N/A	-10	N/A
12/31/2014	N/A	-8	N/A	7	N/A
12/31/2013	N/A	-8	N/A	-8	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CANTAS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CANTAS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CANTAS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CANTAS is forecast to have no revenue next year.

High Growth Revenue: CANTAS is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CANTAS's Return on Equity is forecast to be high in 3 years time

Cantargia Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

No longer forecast to breakeven

Forecast breakeven date pushed back to 2024

Forecast to breakeven in 2023

Recent updates

Cantargia AB (publ) to Report Q1, 2025 Results on May 13, 2025

Cantargia Announces New Data from Two Clinical Studies Strongly Support Nadunolimab Efficacy After Relapse on PD1-Inhibitors

Cantargia AB (publ) Reports Timelines for Nadunolimab Clinical Trials in Leukemia and Triple Negative Breast Cancer

Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer

Cantargia AB (Publ) Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition

Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia

Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis

Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab

Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

Cantargia Reports Phase I Clinical Progress in the CAN10 Project

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer

Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR

Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant

Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases

No longer forecast to breakeven

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10

Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Extends Development of Nadunolimab in Pancreatic Cancer with New Controlled Phase IIb Clinical Trial Following Strong Phase IIb Efficacy Results

Cantargia Appoints Patrik Renblad as Chief Financial Officer

Chief Executive Officer recently bought kr140k worth of stock

Cantargia AB (publ) Successfully Concludes Toxicity Study with Can10 Antibody Ahead of Phase I Clinical Trial Application

Cantargia AB (Publ) Announces Nomination Committee Appointments

Cantargia's CAN10 Demonstrates Positive Activity in Systemic Sclerosis Models in New Data Presented At ACR Convergence 2022

Cantargia AB (Publ) Presents New Data At SITC 2022 Supporting Nadunolimab's Promising Antitumor Clinical Efficacy

Cantargia Reaches Recruitment Milestone and Focuses Nadunolimab Development on Upcoming Randomized Studies

Cantargia AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Cantargia Reports First Non-Squamous NSCLC Patient Treated with Nadunolimab, Keytruda® and Chemotherapy

Cantargia Reports Preclinical Data Demonstrating Unique Treatment Effects of nadunolimab on Pancreatic Cancer Stromal Cells

Cantargia AB (Publ) Publishes Preclinical Data on Strong Anti-Tumor Efficacy of Nadunolimab in Combination with Chemotherapy

Cantargia Reports New Positive Preclinical Efficacy Data for CAN10 Supporting Development in Myocarditis

Cantargia Receives USPTO Notice of Allowance for Composition of Matter Patent on Antibody CAN10

Cantargia AB (Publ) Announces Executive Changes

Cantargia Announces ASCO 2022 Presentation Strengthens Positive Phase IIa interim results for nadunolimab in NSCLC

Cantargia AB (publ) Presents Clinical Interim Results At ASCO 2022 Highlighting the Potential of Nadunolimab in Combination with Checkpoint Inhibitor

Cantargia AB (publ) Reports Positive Preclinical Effects in Atherosclerosis Demonstrating Potential of Can10 in Cardiovascular Disease

Forecast breakeven date pushed back to 2024

Insider recently bought kr88k worth of stock

Cantargia Reports Positive Preclinical Efficacy Data for CAN10 Demonstrating Anti-Fibrotic and Anti-Inflammatory Effects in Systemic Sclerosis

Cantargia AB (Publ) Reports Encouraging New CAN10 Toxicology Results and Schedules Phase I Trial for 2023

Cantargia AB Reports Treatment of First Non-Squamous Non-Small Cell Lung Cancer Patient in New Arm of CANFOUR Study

Cantargia Reports Positive Safety Data from Cirifour Clinical Study on Nadunolimab and Pembrolizumab Combination

Cantargia AB (Publ) Reports Treatment of First Triple Negative Breast Cancer Patient in TRIFOUR Study

Cantargia Advances Nadunolimab Against Pancreatic Cancer in the Pancan Precision Promise[Sm] Phase 2/3 Clinical Trial

Cantargia AB (publ) Reports Updated Encouraging Survival Data from CANFOUR Trial with Nadunolimab and Chemotherapy in Pancreatic Cancer

Cantargia AB (publ) Reports Positive Results for Can10 Antibody in Preclinical Systemic Sclerosis Model

Insider recently bought kr158k worth of stock

Forecast to breakeven in 2023

Cantargia AB (Publ) Announces New Positive Interim Results on Nadunolimab Combination Therapy in NSCLC Published in Abstract for the Annual ESMO Congress

Cantargia AB Completes Patient Recruitment to the Phase IIa Pancreatic Cancer Extension Cohort in the CANFOUR Study

Cantargia AB Reports Preclinical Data Highlighting Advantages of Nadunolimab Mechanism of Action

Cantargia AB Reports First Patient Treated in CAPAFOUR Study Investigating Combination of Nadunolimab with FOLFIRINOX in Pancreatic Cancer

Cantargia Expands CIRIFOUR Trial After Successful Completion of Recruitment in the Pembrolizumab Combination Arm

Cantargia Advances Development of Nadunolimab in Triple Negative Breast Cancer Through Submission of Clinical Protocol for TRIFOUR Study

Cantargia AB (publ) Broadens the Development of Nadunolimab in Three Forms of Cancer and Submits Application for the Phase I/II Clinical Trial CESTAFOUR

Cantargia Receives Regulatory Approval to Start Clinical Trial Investigating Nadunolimab and FOLFIRINOX in Pancreatic Cancer

Chief Financial Officer recently bought kr235k worth of stock

Cantargia AB (Publ) Reports Positive Results in Ongoing Phase IIa Clinical Trial in Pancreatic Cancer Using Nadunolimab and Chemotherapy

Cantargia AB Presents New Preclinical Data Showing Unique Improvement of Heart Function in Myocarditis Using Antibody CAN10

Cantargia AB (Publ) Advance Development of Antibody Can04 by A New Clinical Trial in Triple Negative Breast Cancer

Cantargia AB Presents New Preclinical Data on Antibody CAN10 At Immmunology2021